# Pukang

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pukang

- Industry: Biotechnology
- Headquarters: Chengdu, China
- Website: www.pu-kang.com
- Latest round: Series B (Jun 6, 2024)
- Investors on record: 7

## About

Founded in 2008 and based in Chengdu, China, Pukang is a biotech company that focuses on the research and development of long-acting peptide drug side chains and single-molecule PEG derivatives. In June 2024, the firm closed a series B+ funding. By 2024, the company has a 3,000-square-meter small-scale test laboratory, a 2,000-square-meter pilot laboratory and a 30,000-square-meter production base that meets GMP requirements.

The company's main products include nucleic acid drug raw materials, PEGS blocks and small molecule compounds. PEGS blocks include FMOC-PEG building blocks, Cbz-PEG building blocks and DPEG biotinylated building blocks.

The company’s revenue is generated by providing small molecule PEG derivative molecular blocks.

The company will use the series B+ funding for expanding its R&D pipeline and building a production base of more than 200 acres, and completing the construction and certification of the production base's GMP system.

## Funding rounds

- Series B, Jun 6, 2024 — IDG Capital, Grand Yangtze Capital, Huatai Zijin Investment, Mirae Asset Financial Group, GL Ventures, HM Capital
- Series B, Oct 13, 2023 — Grand Yangtze Capital, Step Fund, Huatai Zijin Investment, GL Ventures
- Series A, Jul 23, 2021 — Grand Yangtze Capital, Step Fund

## Investors

- Grand Yangtze Capital (https://capitalatlas.ai/funds/grand-yangtze-capital) — Series A, Series B
- Step Fund (https://capitalatlas.ai/funds/step-fund) — Series A, Series B
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B
- IDG Capital (https://capitalatlas.ai/funds/idg-capital) — Series B
- Mirae Asset Financial Group — Series B
- HM Capital (https://capitalatlas.ai/funds/hm-capital) — Series B